Articles

Jun
13

A genome editing revolution of unprecedented magnitude— spearheaded by a scientific breakthrough called CRISPR—is underway. This powerful technology has enabled scientists to precisely edit genes and is challenging long-held conventions of how humans view life. The incipient power to control and alter the genetic destiny of living organisms, including plants and animals intended for human

Jun
13

Grid modernization holds the alluring promise of rationalizing electricity pricing, saving consumers money, and improving environmental quality all at the same time. Yet, we have seen only limited and patchwork regulatory initiatives towards significant grid modernization in the United States. Outside of a few leading states, state energy regulators appear loath to embrace full- throated

Jun
13

An array of new state policies and declining costs for clean energy technologies have opened electricity markets to many new participants, including electric utilities’ own customers. Most low- income customers, however, lack the resources to access these markets. Indeed, low-income customers already face disproportionately high energy and transportation burdens. Regulators and utilities have expressed concerns

May
12

For the most part, United States patent law is only concerned with activities that take place in the United States and its territories. One of the rare exceptions to this may be found in 35 U.S.C. § 271(f). The first part of this statute makes it an act of infringement for a party in the

May
06

Michael Rothwell previously published an article, Patents and Public Rights: The Questionable Constitutionality of Patents Before Article I Tribunals After Stern v. Marshall, in JOLT’s Volume 13, back in 2012. In response to a rebuttal piece, Michael Rothwell wrote this current piece to further discuss the relevant issues of the constitutionality of Article I post-grant

Apr
17

The financial technology field is a rapidly growing sector that threatens to disrupt established financial institutions and their accompanying regulatory structure. New types of financial services and products do not fit neatly into the current regulatory landscape, which has hampered growth and competition with traditional financial institutions. This article advances the idea that the Office

Apr
17

The Food and Drug Administration (“FDA”), tasked with promoting and protecting public health, has long been recognized as the gatekeeper for drugs. However, the agency has not been immune from criticism from patients and industry stakeholders over its time-consuming and clinical data-driven approval processes, alleged to hinder potentially effective drugs from reaching the market as

Categories